On a sunny September day in 2023, scientists at CRISPR Therapeutics invited me to peer through their microscopes. Through the ...
Spotlight Therapeutics, a startup with a bold vision for delivering CRISPR therapies into the body without the ...
The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic diseases to ...
Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
Gene editing techniques may one day allow for the removal of the extra chromosome that causes Down syndrome, early ...
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback